Healthcare
OmniAb Names Amechi Nwachuku Chief Operating Officer
EMERYVILLE, Calif., July 13, 2026--OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer, effective today. Mr. Nwachuku will be primarily responsible for managing the strategy, operations and commercial maximization of xPloration®, OmniAb’s proprietary, innovative high-throughp
About this update from Omniab, Inc.
EMERYVILLE, Calif., July 13, 2026 --( BUSINESS WIRE )--OmniAb, Inc. (NASDAQ:OABI) , a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer, effective today. Mr. Nwachuku will be primarily responsible for managing the strategy, operations and commercial maximization of xPloration®, OmniAb's proprietary, innovative high-throughput single B-cell screening platform. Mr. Nwachuku has more than 25 years of experience, including leading multi-billion-dollar global life sciences tools businesses, with responsibility for driving commercial strategy, sales, marketing and integrated operations. Most recently, Mr. Nwachuku served as Vice President of Global Commercial Genetic Sciences at Thermo Fisher Scientific, and prior to that as Senior Vice President, Global Commercial, SCIEX at Danaher Corporation. Mr. Nwachuku also held senior executive roles within the Beckman Coulter Diagnostics business at Danaher and international leadership positions at Johnson & Johnson Diabetes Care and Bayer. Early in his career, he served as a management consultant at McKinsey & Company. He earned a Bachelor of Science in Chemical Engineering and his Master of Business Administration (MBA) from the Massachusetts Institute of Technology (MIT). "Amechi is a seasoned global leader whose extensive experience and perspectives will further strengthen our executive management team," said Matt Foehr, President and Chief Executive Officer of OmniAb. "Throughout his career, Amechi has established a proven track record of commercial and operational excellence, consistently driving growth, capitalizing on market opportunities, and efficiently creating value. Through ongoing discussions with our partners and market research, we've gained increasing confidence in the market opportunity for our xPloration platform. At the same time, our core antibody discovery technology licensing business continues to deliver strong performance, supported by a growing portfolio of high-value milestone and royalty-bearing programs. We believe that xPloration can be a meaningful complement to our licensing business, significantly expanding our growth opportunities and further diversifying our future revenue streams." Mr. Nwachuku added, "I am excited to join the innovative team at OmniAb, which has already demonstrated the power of its xPloration platform and its potential to make a meaningful impact in the lab. My enthusiasm only grew as I learned more about the company, its differentiated technologies and the growth potential of xPloration, designed to meet the industry's growing demand for large datasets and reliable, easy-to-use, high-throughput screening. I am proud to join OmniAb and look forward to helping take it to the next level."